Compare Cassava Sciences Inc (FLNA) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.16 (market cap $17.89B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 454.1× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 44,866,592). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days on average.
| FLNA | HYG | |
|---|---|---|
Market Cap | $39.40M | $17.89B |
Volume | 759,018 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $81.28 |
52-Week Low | $0.68 | $76.90 |
Typical Hold Time | 37 Days | 59 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces pressure from rising Treasury yields impacting high-yield bond valuations. Recent dividend payments of $0.34-$0.44 provide income support amid market volatility.
The outlook remains challenged by persistent bond market selloffs and higher interest rates, though the current yield environment may attract income-seeking investors. Key risks include further Fed tightening and economic slowdown impacting corporate credit quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
